RUMORED BUZZ ON ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Section C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will receive treatment until finally sickness progression or perhaps the contributors are not able to tolerate the study drugs.88 These preclinical studies give paradigms for upcoming clinical trials in AML,